Provided by Tiger Trade Technology Pte. Ltd.

Arcus Biosciences Inc.

26.15
-2.3400-8.21%
Post-market: 26.150.00000.00%19:30 EDT
Volume:2.39M
Turnover:63.89M
Market Cap:3.33B
PE:-6.77
High:28.46
Open:28.02
Low:25.91
Close:28.49
52wk High:31.74
52wk Low:11.30
Shares:127.33M
Float Shares:89.84M
Volume Ratio:2.05
T/O Rate:2.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8641
EPS(LYR):-3.2900
ROE:-90.82%
ROA:-30.39%
PB:7.18
PE(LYR):-7.95

Loading ...

Arcus Biosciences Coverage Assumed by Truist Securities at Buy

Dow Jones
·
May 18

Arcus Biosciences assumed with a Buy at Truist

TIPRANKS
·
May 18

U.S. RESEARCH ROUNDUP-Exxon Mobil, Northrop Grumman, Regeneron Pharmaceuticals

Reuters
·
May 18

Arcus CFO Robert C. Goeltz II disposes 7,763 shares worth $198,913.69

Reuters
·
May 13

Arcus Biosciences Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
May 12

Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley

TIPRANKS
·
May 11

Earnings Flash (RCUS) Arcus Biosciences Posts Q1 EPS -$1.02, vs. FactSet Est of -$0.88

MT Newswires Live
·
May 06

Stock Track | Arcus Biosciences Plunges 5.49% After-Hours on Disappointing Q1 Earnings Miss

Stock Track
·
May 06

Arcus Biosciences Q1 EPS $(1.02) Misses $(0.93) Estimate, Sales $17.000M Miss $29.484M Estimate

Benzinga Earnings
·
May 06

Arcus Q1 net loss widens to $128 million; revenue falls to $17 million

Reuters
·
May 06

BRIEF-Arcus Biosciences Q1 Net Income USD -128 Million

Reuters
·
May 06

Arcus Biosciences Q1 Revenue USD 17 Million VS. Ibes Estimate USD 29.5 Million

THOMSON REUTERS
·
May 06

Arcus Biosciences Q1 Pretax Profit USD -128 Million

THOMSON REUTERS
·
May 06

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Simply Wall St.
·
May 04

Earning Preview: Arcus Biosciences Inc. this quarter’s revenue is expected to decrease by 19.31%, and institutional views are bullish

Earnings Agent
·
Apr 28

Assessing Arcus Biosciences (RCUS) Valuation After STAR-121 Termination And Gilead Option Changes

Simply Wall St.
·
Apr 27

Arcus Biosciences grants new hire options for 4,200 shares, RSUs for 2,100 shares

Reuters
·
Apr 25

Arcus Biosciences rises 12.2%

TIPRANKS
·
Apr 22

Arcus Biosciences schedules conference call on quarterly results, pipeline update

Reuters
·
Apr 22

Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says

MT Newswires Live
·
Apr 22